INT284669
From wiki-pain
(Difference between revisions)
Latest revision as of 19:37, 21 September 2012
Context
|
Info
|
Confidence
|
0.65
|
First Reported
|
2009
|
Last Reported
|
2010
|
Negated
|
0
|
Speculated
|
0
|
Reported most in
|
Body
|
Documents
|
3
|
Total Number
|
6
|
Disease Relevance
|
4.58
|
Pain Relevance
|
1.14
|
|
|
|
[edit] Sentences Mentioned In
Key:
|
Protein
|
Mutation
|
Event
|
Anatomy
|
Negation
|
Speculation
|
Pain term
|
Disease term
|
0.82 (95% CI:0.740.91)), LRRK2/MUC19 (rs11175593, P?
|
|
1)
|
Confidence
|
0.65
|
Published
|
2010
|
Journal
|
PLoS Genetics
|
Section
|
Abstract
|
Doc Link
|
PMC2996314
|
Disease Relevance
|
0.85
|
Pain Relevance
|
0.41
|
|
0.82 (95% CI:0.740.91)), LRRK2/MUC19 (rs11175593, P?
|
|
2)
|
Confidence
|
0.65
|
Published
|
2010
|
Journal
|
PLoS Genetics
|
Section
|
Abstract
|
Doc Link
|
PMC2996314
|
Disease Relevance
|
0.85
|
Pain Relevance
|
0.42
|
|
0.83 (95% CI:0.760.91)), LRRK2/MUC19 (rs11175593, P?
|
|
|
0.83 (95% CI:0.760.91)), LRRK2/MUC19 (rs11175593, P?
|
|
|
However, transgenic LRRK2 expression also led to a preferential loss of dopaminergic neurons, with G2019S fPD LRRK2 being measurably more toxic than wild type LRRK2.
|
|
|
Saha et al [63] have recently shown that knockdown of lrk-1 sensitizes worms to the mitochondrial toxic rotenone, while pan-neuronal expression of wild type human or G2019S fPD LRRK2 (driven by the snb-1 promoter) protects against rotenone toxicity.
|
|
|
This test has worked.